Cargando…
Tumor Microenvironment Responsive CD8(+) T Cells and Myeloid‐Derived Suppressor Cells to Trigger CD73 Inhibitor AB680‐Based Synergistic Therapy for Pancreatic Cancer
CD73 plays a critical role in the pathogenesis and immune escape in pancreatic ductal adenocarcinoma (PDAC). AB680, an exceptionally potent and selective inhibitor of CD73, is administered in an early clinical trial, in conjunction with gemcitabine and anti‐PD‐1 therapy, for the treatment of PDAC. N...
Autores principales: | Chen, Qiangda, Yin, Hanlin, He, Junyi, Xie, Yuqi, Wang, Wenquan, Xu, Huaxiang, Zhang, Lei, Shi, Chenye, Yu, Jun, Wu, Wenchuan, Liu, Liang, Pu, Ning, Lou, Wenhui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667825/ https://www.ncbi.nlm.nih.gov/pubmed/37867243 http://dx.doi.org/10.1002/advs.202302498 |
Ejemplares similares
-
CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer
por: Chen, Qiangda, et al.
Publicado: (2020) -
Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
por: Piovesan, Dana, et al.
Publicado: (2022) -
Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study
por: Pu, Ning, et al.
Publicado: (2023) -
Chemokine C‐C motif ligand 21 synergized with programmed death‐ligand 1 blockade restrains tumor growth
por: Chen, Qiangda, et al.
Publicado: (2021) -
Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma
por: Faraoni, Erika Y., et al.
Publicado: (2022)